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Abstract 
Glaucoma is the leading cause of irreversible blindness worldwide, and is a major cause 
of blindness in the United States. It affects approximately 5% of Caucasians and 10% of African-
Americans over the age of 60 years. Elevated intraocular pressure (IOP) is currently the only 
modifiable risk factor for glaucoma. Impaired outflow of aqueous humor from the eye is thought 
to be the cause of pathologically elevated IOP. However, the etiology of outflow impairment is 
unknown. Anatomically, the aqueous humor drains into the iridocorneal angle of the eye, where 
the iris inserts at the transition between the cornea and sclera. In humans, approximately 80-90% 
of the aqueous traverses through the trabecular meshwork (TM), juxtacanalicular connective 
tissue (JCT), Schlemm’s canal, collector channels and empties into episcleral veins. 
Abnormalities at these sites are thought to cause impaired outflow. Abnormal accumulation of 
extracellular matrix (ECM) in the TM or JCT, abnormal endothelial function in Schlemm’s 
canal, or a combination of these components have been strongly implicated. Our laboratory has 
focused on the role of Secreted Protein Acidic and Rich in Cysteine (SPARC) in regulating 
outflow. SPARC is the prototypical matricellular protein that mediates ECM organization and 
turnover in numerous human tissues. Our lab was first to demonstrate that SPARC is highly 
expressed in the TM and JCT regions of the eye, and that the SPARC knockout (KO) mouse has 
a significant decrease in IOP of 15-20%. SPARC may affect the degree of segmental flow, a 
theory that states that variable aqueous outflow occurs around the circumference of the eye; only 
certain portions of the TM are thought to display active outflow at any particular moment. 
The cytokine transforming growth factor-ß2 (TGFß2) has been shown to modulate 
multiple ECM proteins, including SPARC. TGFß2 is significantly upregulated by 2 to 3-fold in 
the aqueous humor of glaucoma patients compared to controls. In addition, when TGFß2 is 
overexpressed in rodent eyes, increased ECM deposition is observed within the trabecular  
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meshwork leading to IOP elevation. SPARC is one of the most highly upregulated proteins by 
TGFß2, and is downstream of TGFß2.  
We hypothesized that wild-type (WT) mice would demonstrate segmental flow, while 
SPARC KO mice would display a more continuous pattern of outflow around the eye. We also 
believed that IOP would be inversely correlated with outflow area. We also hypothesized that 
SPARC is essential to the process of TGFß2-mediated ocular hypertension, and that the lack of 
SPARC would impair IOP elevation. 
We conducted a tracer study utilizing fluorescent microbeads to determine the location of 
outflow circumferentially around the mouse TM. Microbeads were injected intracamerally into 
the eyes of WT and KO mice. After a 45-minute incubation period, the mice were euthanized 
and eyes were processed for confocal, light, and electron microscopy. During the second group 
of experiments, empty or TGFß2-containing adenovirus was injected intravitreally into WT and 
SPARC KO mice and IOP was measured for 2 weeks. Immunohistochemistry was completed on 
all tissues to assess for changes in major ECM proteins.  
Percentage effective filtration length (PEFL), or area of the TM labeled by tracer, was 
significantly increased in SPARC KO mice (70.61% ± 11.36%, p<0.005; N=11) compared to 
WT mice (54.68% ± 9.95%; N=11). In addition, the pressures between the two sets of eyes were 
significantly different with mean pressures of 16.3 mm Hg in WT mice and 12.6 mm Hg in KO 
mice (p<0.005, N=11 pairs). In addition, PEFL and IOP were inversely correlated with R
2 = 0.72 
(N=10 pairs); in eyes with higher IOP, PEFL was reduced. Electron microscopy demonstrated 
that high-tracer TM areas had a greater separation between trabecular beams. Collagen fibril 
diameter was found to be smaller in the KO (28.272 nm) compared to WT (34.961 nm; 
p<0.0005, N=3 pairs). These data provided structural correlations to the functional data 
regarding segmental flow.  
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In the second set of experiments, IOP was found to be significantly elevated in TGFß2-
injected WT mice compared to empty vector-injected WT mice during days 4-11 (p<0.05, N=8). 
However, IOP was not significantly elevated in TGFß2-injected KO mice compared to controls. 
Immunohistochemistry demonstrated that TGFß2 increased expression of collagen IV, 
fibronectin, plasminogen activator inhibitor-1 (PAI-1), connective tissue growth factor (CTGF), 
and SPARC within the TM of WT mice, but only PAI-1 and CTGF in KO mice (p<0.05, N=3 
pairs).  
These data support our hypotheses, indicating that SPARC plays an integral role in the 
modulation of aqueous humor outflow. In addition, it appears as though SPARC is essential to 
the regulation of TGFß2-mediated ocular hypertension. Aside from providing further evidence of 
the importance of ECM in IOP regulation, our work presents the novel discovery of segmental 
flow in the mouse. Given the potential role of SPARC in TGFß2-mediated ocular hypertension, 
SPARC may not only play an integral role in ECM homeostasis within the trabecular meshwork, 
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Glossary 
Ad.empty  Sham (empty) adenovirus 
Ad.TGFß2  TGFß2-containing adenovirus 
ECM    Extracellular matrix 
JCT    Juxtacanalicular connective tissue 
KO    Knockout 
POAG   Primary open-angle glaucoma 
SC    Schlemm’s canal 
SPARC  Secreted Protein Acidic and Rich in Cysteine 
TGFß2   Transforming growth factor ß2 
TIMP    Tissue inhibitor of metalloproteinase 
TM    Trabecular meshwork 
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Introduction 
Glaucoma is a major cause of blindness, affecting over 67 million people worldwide
1. In 
the United States, the prevalence is approximately 5% in Caucasians and 10% in African-
Americans
2, 3. While surgical treatments exist, medical therapies have been quite limited due to 
the lack of insight into the molecular mechanisms behind glaucoma pathogenesis. Elevated 
intraocular pressure (IOP) is the greatest risk factor contributing to primary open angle glaucoma 
(POAG)
4, the more prevalent form of glaucoma. Intraocular pressure is determined by the 
balance of secretion and drainage of aqueous humor, the natural nutrient fluid for the cornea, 
lens, and trabecular meshwork (TM). Aqueous drains through either the TM or the ciliary body 
face, both of which are located at the iridocorneal angle where the iris inserts into sclera (Figure 
1). The TM extends circumferentially around all 360 degrees of the eye.  The proportion of flow 
between the trabecular meshwork and ciliary body changes with age; in the adult age range of 
POAG, approximately 80-90% of aqueous humor drains through the TM.  After passing through 
the TM, the fluid traverses through Schlemm’s canal (SC), collector channels, and finally 
empties into episcleral veins (Figure 2). The remaining aqueous humor exits through an 
alternative pathway, the uveoscleral pathway (Figure 1). While the uveoscleral pathway is 
manipulated by some glaucoma medications in order to reduce IOP, it is not believed to 
contribute to outflow dynamics in older eyes
5. 
The elevated IOP of POAG is due to impaired outflow through the TM
6. No defect in 
aqueous production or drainage through the ciliary body has yet been identified to cause an 
elevated IOP. The TM is a complex structure of three layers.  The two innermost layers consist 
of endothelial cell-lined supporting beams or fenestrated sheets
6. The outermost layer, the 
juxtacanalicular connective tissue (JCT) region, is an amorphous zone of extracellular matrix  
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(ECM) amongst a small number of cells supported by an incomplete basement membrane, with 
TM cells on the inner side and cuboidal Schlemm’s canal inner wall cells on the outer side
6, 7.  
The JCT undergoes constant remodeling. Cells within the JCT are thought to respond to 
sustained IOP fluctuations by altering the balance of matrix metalloproteinases (MMPs) and 
tissue inhibitors of metalloproteinases (TIMPs); these alter the quantity and quality of ECM, 
thereby leading to modulation of outflow resulting in IOP homeostasis
8-10. One theory is that in 
glaucomatous eyes, the loss of TM cellularity likely causes an impaired homeostatic response, 
thereby causing dysfunctional IOP regulation
11, 12. Consistent remodeling appears to be essential 
to IOP maintenance.  
The role of ECM in outflow regulation and the location of greatest resistance within the 
iridocorneal angle has been the focus of a great body of literature. Various tissues in the angle 
are potential sources of resistance: TM, SC, collector channels, and episcleral veins. However, 
numerous studies have demonstrated that resistance generated within the SC, collector channels, 
and episcleral veins is minor
13-15. Earlier studies conducted in the late 1980s demonstrated that in 
monkeys, a significant portion of IOP reduction occurs slightly upstream of SC, seemingly 
pointing to the JCT as a key regulatory zone
16, 17. Further studies demonstrated that the JCT is 
the anatomic location of the majority (66-76%) of outflow resistance
6, 7. In today’s literature, the 
synergistic interaction between the JCT, SC endothelium, and the associated fenestrated 
basement membrane is thought to be the essential component in modulating outflow resistance 
and IOP
16, 17 (Figure 2). Additional studies comparing normal and glaucomatous human eyes 
found the greatest difference in JCT morphology; glaucomatous eyes had a significantly thicker 
JCT region compared to controls
18
. The quick-freeze/deep-etch methodology used to evaluate 
ECM ultrastructure demonstrated that the JCT contains an intricate mixture of ECM with large 
open spaces lacking ECM
19. It is suspected that substances such as proteoglycans and  
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glycosaminoglycans may account for some of the resistance within the JCT, but this has been 
challenging to demonstrate using current techniques. SD plaques have been shown to accumulate 
in this region, which highlight the importance of the JCT in glaucoma pathogenesis
20, 21; SD 
plaques are protein aggregates within the TM that correlate with optic nerve damage in 
glaucomatous human eyes
22. The JCT region is therefore thought to be a critical component in 
determining aqueous outflow and potentially in the pathogenesis of glaucoma.  
The regulation of aqueous outflow between the JCT and SC endothelium is described by 
the funneling hypothesis, which states that the aqueous humor funnels through a finite number of 
pores in the SC endothelium. The funneling process is altered by variation in the distance 
between the JCT and SC endothelium
23. Aqueous humor does not exit the anterior chamber of 
the eye uniformly throughout the 360 degrees of the iridocorneal angle; rather, outflow occurs 
preferentially at points where there is a more sizeable separation between the JCT and SC 
endothelium, as well as where there is a higher concentration of pathways leading to episcleral 
veins
24. In contrast, flow is reduced in regions where the SC has collapsed, an observation noted 
in several eyes with high IOP
25. This concept is referred to as segmental flow. An initial study 
utilizing cationic ferritin first confirmed the segmental nature of outflow in normal human eyes
26. 
In addition, cell-ECM interactions in this region have been found to mediate resistance 
generation, thereby affecting segmental flow and IOP
8. Segmental flow has clinical implications 
in the surgical management of glaucoma. Various TM bypass shunts have been developed in the 
past few years, such as the iStent
27. It has been anecdotally discovered that multiple stents are 
often needed to obtain a substantial decrease in IOP, as one or two devices are often placed in 
areas of pre-existing high outflow, which does not augment outflow. 
  Multiple research groups have used microbead tracers to assess segmental flow and have 
identified an association between IOP and outflow. Zhang et al. treated monkeys with argon  
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laser photocoagulation (a simulation of ocular hypertension in glaucomatous eyes), which led to 
a 3-fold increase in IOP but a 6-fold decrease in the total TM area utilized for outflow
28. In 
addition, the average distance between the two walls of SC was 5-fold lower in laser-treated eyes 
compared to control eyes, indicating the role of SC collapse in ocular hypertension. The authors 
concluded that laser damage reduces the available area for outflow, thereby elevating IOP; 
however, no association data was presented. Similarly, Lu et al. showed that WT control eyes 
demonstrated segmental flow, while eyes treated with the Rho-kinase inhibitor Y-27632 had a 
more uniform or homogeneous pattern
24. In addition, treated eyes had a 3-fold increase in the 
total TM area utilized for outflow, with the JCT and SC wall much more distended. Again, the 
structural differences in the TM appear to dictate outflow. In the latter study, the authors 
demonstrated that outflow facility, the reciprocal of resistance to aqueous humor outflow as it 
leaves the eye, is proportional to the area of TM utilized for outflow. Other groups have utilized 
fluorescent tracers for anatomic purposes; Lindsey et al. and Camelo et al. utilized fluorescent 
dextrans to study aqueous outflow in the rat and mouse
29-33. The uveoscleral outflow pathway 
was identified with these techniques in addition to other associated anatomy.  
Molecular biology laboratories studying the JCT region have traditionally focused on the 
TM cells or surrounding ECM. Regarding the former, increase in actin stiffness and the 
development of cross-linked actin networks (CLANs) have been shown to induce a more rigid 
morphology in TM cells, leading to decreased outflow
34-36.  Various pharmacologic compounds 
have been shown to decrease the formation of such stress fibers, leading to increased outflow. 
These include ethacrynic acid, latrunculins, and Rho-kinase (ROCK) inhibitors
37-42, some of 
which are currently being evaluated in clinical trials. 
  Our laboratory investigates the coordinated regulation of ECM in the TM and its effect on 
IOP.  Germaine to this specific work is the role of Secreted Protein Acidic and Rich in Cysteine  
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(SPARC). SPARC is a matricellular glycoprotein, or a protein that allows cells to communicate 
with and control their surrounding ECM. Matricellular proteins mediate ECM organization and 
turnover in various tissues by altering the balance of MMPs and TIMPs, an essential process that 
occurs within the TM as previously discussed. SPARC is found throughout the human body, and 
is expressed at a higher level in disease states such as renal fibrosis, hepatic fibrosis, and 
carcinomas
43, 44. SPARC has been shown to enhance fibronectin-induced ECM assembly
45, while 
its removal causes a decrease in the expression of several collagens
46. SPARC-null mice are 
prone to several conditions, such as attenuated collagen and connective tissue, poor closure of 
open wounds, osteopenia, and an impaired reaction against implanted materials
47-50. SPARC 
appears to have a strong role in ECM regulation.  
  In the eye specifically, SPARC can be identified in the aqueous humor and is one of the 
most highly expressed gene products in the TM
51. Expression is significantly increased when TM 
cells are stretched, a physiologic and pathophysiologic consequence of IOP, which may provide 
additional clues into glaucoma pathogenesis
52. In addition, SPARC has been implicated in the 
formation of cataract and corneal repair
53-55. Various matricellular proteins other than SPARC, 
such as thrombospondins-1 and 2, hevin, tenascins-C and X, and osteopontin, have been studied 
in the eye. However, SPARC has a much stronger impact on IOP than any of these proteins
56. 
Our lab has demonstrated that SPARC is highly expressed in the human TM
57, and that the 
SPARC-null mouse demonstrates a significant decrease in IOP of 15-20%
58. The aqueous 
drainage pathway in mice is remarkably similar to humans, making it an excellent animal model 
with findings that are likely applicable to human physiology. We have also demonstrated that 
when SPARC is overexpressed in perfused human anterior segments, IOP increases by 25-30% 
with a significant upregulation of fibronectin, collagen I, and collagen IV within the TM
59. Thus, 
the mechanism of how SPARC modulates IOP and potentially contributes to glaucoma  
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pathogenesis warrants further study. 
Transforming growth factor ß2 (TGFß2), a critical cytokine in development and tissue 
growth, has been shown to regulate SPARC and many other ECM proteins in the TM
60-65. 
Clinically, TGFß2 is elevated approximately 2 to 3-fold in the aqueous humor of POAG patients 
66-69. In vitro, TGFß2 is significantly elevated in cultured glaucomatous TM cell lines compared 
to normal TM cell lines
70. In perfused human cadaveric anterior segments, treatment with TGFß2 
in the perfusion medium elevates IOP and decreases outflow facility
63, 71. Additionally, in mouse 
and rat models, injection of TGFß2-containing adenovirus leads to a significant increase of 
IOP
64. The increases in IOP are likely related to changes in ECM, as fibronectin and 
plasminogen activator inhibitor-1 (PAI-1) are upregulated by TGFß2 in the TM of both perfused 
cadaveric anterior segments and mouse eyes
64, 65, 71-76. Thus, TGFß2 and ECM alteration appear 
to have a critical role in POAG development. TGFß2 appears to regulate SPARC via the Smad 
2/3, JNK, and p38 pathways in human TM endothelial cells
77, 78, and SPARC is the most highly 
upregulated protein in TM cells after TGFß2 stimulation
62. SPARC may therefore be a critical 
regulatory node in TGFß2-mediated ocular hypertension.  
While there has been substantial progress in our understanding of ECM proteins in 
glaucoma pathogenesis, the role of specific proteins and pathways are still unclear. Various 
hypotheses have been postulated, one of which predicts that the amount of ECM in the TM 
correlates with the amount of outflow resistance, which is supported by intravitreal TGFß2 
delivery 
8, 79-82. In addition, the association between the proportion of area utilized for outflow 
and IOP has not been formally studied. We hypothesized that wild-type mice would exhibit 
segmental flow, while SPARC knockout mice would display more uniform outflow due to 
altered ECM production. We also hypothesized that there would be an inverse correlation 
between the IOP of a mouse eye and the area involved in active outflow. Finally, we  
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hypothesized that TGFß2-mediated ocular hypertension would be attenuated in the SPARC-null 
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Methods 
Animal Husbandry 
All experiments were completed in compliance with the Association for Research in 
Vision and Ophthalmology (ARVO) Statement for the use of Animals in Ophthalmic and Vision 
Research. Local Institutional Animal Care and Use Committee (IACUC) approval was obtained. 
C57BL6-SV129 wild type mice and SPARC-null mice with the same background strain were 
originally obtained by generous donation from E. Helene Sage of the Benaroya Research 
Institute at Virginia Mason (Seattle, WA). Heterozygotes were bred together, and their offspring 
were subsequently genotyped in order to identify homozygous SPARC-null mice, which were 
used in these experiments. In addition, wild-type (WT) and SPARC knockout (KO) breeding 
pairs were used to increase offspring yield for no more than 1-2 generations in order to limit 
genetic drift. Animals used in the adenovirus experiments were between 5 and 8 weeks in age. 
All were housed in the animal biosafety level-2 suite of the Schepens Eye Research Institute 
animal facility. Animals used in all experiments were housed either in the animal facilities of 
Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute. 
Passive Binding Assay 
To ensure that the affinity for the fluorescent microbead tracer (FluoSpheres carboxylate-
modified 20-nm microspheres; Invitrogen, Eugene, OR) utilized in these studies did not differ 
between the TMs of WT and SPARC-null tissue, WT & KO eyes were passively bathed in a 
microbead solution. Age and temporally matched WT and KO mice were sacrificed and their 
freshly enucleated eyes were placed in Dulbecco’s Modified Eagle Medium (DMEM) solution. 
The eyes were then dissected, with the removal of the posterior segment and lens. The anterior  
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segment was then incubated in a 1:50 solution of microbeads in 1X Dulbecco’s Phosphate 
Buffered Saline (DPBS) -/- (Invitrogen, Eugene, OR) (identical to the injected solution in later 
studies) for 4 hours in a 37ºC water bath on a shaker, or overnight at 4ºC on a shaker. The tissue 
was then fixed in Karnovsky’s fixative (KII) and sectioned into 6-8 sections. Fluoroscopy of the 
tissue en face was then completed using an Olympus FSX100 fluorescence microscope 
(Olympus, Center Valley, PA) with an exposure time of 1/55 second. Images were stitched 
together using CellSens Imaging Software (Olympus, Center Valley, PA) and fluorescence was 
quantified using ImageJ software (NIH, Bethesda, MD). Total corrected fluorescence (TCF) was 
calculated for each section as TCF = integrated density – (area of TM section * mean 
background fluorescence), akin to calculations in various publications
83, 84. Mean background 
fluorescence was averaged from 4 different areas adjacent to the TM. TCF values for the various 
sections were then averaged to determine the mean TCF value for that eye. Tissue was then 
analyzed by confocal and electron microscopy.  
IOP measurement 
Age and temporally matched C57BL6-SV129 wild-type (WT) and SPARC knockout 
(KO) mice were used. In the segmental flow experiments, each mouse was anesthetized with an 
intraperitoneal injection of 5 µL/g anesthesia (90 mg/kg ketamine + 9 mg/kg xylazine; Phoenix 
Pharmaceutica, St. Joseph, MO). A rebound tonometer (TonoLab; Colonial Medical Supply, 
Franconia, NH) was used to measure the IOP of the right eye six times between 4 and 7 minutes 
after the anesthetic injection. This time period was selected due to prior studies indicating that 
the IOP is stable during this time
82, 85, 86. This was repeated three times, and the mode of each set 
was calculated and averaged, which was recorded as the IOP for that mouse. The tonometer was 
fixed horizontally and a pedal was used to initiate measurements to eliminate potential artifact  
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caused by handling of the device. The probe tip was approximately 2-3 mm from the eye at 
resting state, and the mouse was positioned to allow the probe to contact the central cornea 
perpendicularly. The accuracy of the rebound tonometer in measuring IOP has been previously 
validated in our species of WT and KO mice
58. All measurements and injection experiments 
were conducted between 11 AM and 3 PM to minimize the potential artifact from circadian 
variability on IOP
58.  
IOP Measurement under Anesthesia 
To demonstrate that IOP remains stable under an inhaled anesthetic, measurements were 
completed using isoflurane. Age and temporally matched WT and KO mice were used. Each 
mouse was anesthetized with 2-4% isoflurane (IsoSol; Vedco, St. Joseph, MO) in 1-2 L/min 
100% oxygen in a closed chamber; a timer was started when isoflurane was released into the 
chamber. After precisely 70 seconds, the sedated mouse was moved to a facemask, through 
which it received 1-1.5% isoflurane mixed with the same concentration of oxygen. IOP was 
measured every minute between 4 and 15 minutes on either the left or right eye (randomly 
chosen for each mouse) without adjusting the stand or tonometer as detailed above. IOP was not 
measured before 4 minutes, as the mouse was not sufficiently anesthetized prior to this time to 
allow corneal contact. Artificial tears were not administered, as a previous trial demonstrated that 
it caused aberrations in IOP measurement (data not shown). The cornea appeared to be normal 
under the current study conditions. 
Microbead injection  
Mice were then stabilized on a mounting stage (Stoelting Co., Wood Dale, IL) under a 
zoom-dissecting microscope. The animal was positioned such that the eye was as horizontal as  
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possible (i.e., iris plane parallel to the stage) in order to ensure even distribution of tracer 
throughout the anterior chamber. A 10 µl Hamilton microsyringe (Nanofil; World Precision 
Instruments, Sarasota, FL) was loaded with 1 µL of 1:50 solution of microbead tracer diluted in 
1X DPBS -/-, as well as 2 µL of KII solution separated by a 0.1 µL air bubble. Smaller 20-nm 
microspheres were utilized to ensure that the IOP did not artificially elevate from mechanical 
blockage from the beads themselves. Multiple rinses with the tracer were completed in order to 
prevent contamination of the tracer volume in the syringe with KII solution. A 35G needle 
(NF35BL-2, World Precision Instruments, Sarasota, FL) connected to this syringe was then 
inserted into the right eye anterior chamber centrally to optimize uniform, intracameral 
distribution of the tracer. The tracer volume was then delivered at 4 nL/second, by a 
microprocessor-based microsyringe pump controller (Micro4; World Precision Instruments, 
Sarasota, FL).  Lubricating eye drops (Nature’s Tears (hypromellose 0.4%); Rugby Laboratories, 
Duluth, GA) were applied to the exterior of the eye in order to prevent dehydration. The 12 
o’clock position of the eye was marked using tissue marker dye (Triangle Biomedical Sciences, 
Durham, NC) to provide orientation. At 30 minutes, half of the original dose of anesthesia 
administered was given in order to maintain the mouse at the appropriate level of sedation.  
A time-course experiment was first performed to determine the optimal incubation time 
for tracer to migrate through the anterior chamber and strongly penetrate the TM and SC. This 
was found to be 45 minutes, which was then used for all further experiments. The needle 
remained in the eye during this period, and 2 µL of KII solution was subsequently injected into 
the anterior chamber of each eye. KII solution was also simultaneously applied to the exterior of 
the eye multiple times using a plastic dropper. After 30 minutes of fixation, the mouse was 
sacrificed by anesthetic overdose (4x the original dose), and the eyes were enucleated using a 
lateral canthotomy technique to reduce trauma to the globe. Eyes were placed in KII solution at  
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4ºC overnight. If precipitated tracer was observed within the syringe or if the needle made 
contact with the lens, the experiment was abandoned due to the reduction in effective tracer 
concentration.  
Tissue handling for confocal microscopy 
After overnight fixation, each eye was dissected, with the posterior cup and lens removed 
and the anterior portion partially dissected into 6-8 sections in a “sunflower”-like pattern. The 
eye was mounted on a slide, with the orientation of the tissue maintained by orienting the tissue 
with the superior portion placed superiorly on the slide. Sections were viewed en face, and radial 
and frontal sections were prepared and examined.   
Although auto-fluorescence of the iris was noted, this tissue was not removed due to the 
potential loss or disruption of TM tissue during that process. Fluorescence in the sample was 
then visualized using a confocal microscope (Carl Zeiss 510 Axiovert M100 Laser Scanning 
Microscope; Carl Zeiss, Heidelberg, Germany) with a 10X objective and a pinhole of 169 µm in 
order to capture the entire fluorescence throughout the thickness of the tissue. The tissue was 
imaged through the corneal side in order to visualize the fluorescent tracer in the TM. Compiling 
a set of Z-stack images and quantifying the fluorescence confirmed the same intensity and 
overall pattern as seen with the large pinhole setting. Images of each of the 6-8 sections of the 
tissue were captured and analyzed using the Zeiss LSM 510 operating software (Carl Zeiss, 
Heidelberg, Germany). 
The tissue was subsequently sectioned in both radial and frontal planes. Sections were 
stained with 1:1000 TO-PRO-3 (Invitrogen, Eugene, OR) for 30 minutes, followed by three 10-
minute washes using 1X DPBS. Radial sections were then evaluated using confocal microscopy  
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to identify TM and SC, as well as episcleral veins. Frontal sections, orthogonal to radial sections, 
were then prepared with the guidance of the previously observed fluorescence. 
Analysis of Percent Effective Filtration Length (PEFL)   
Images were then analyzed to quantify the overall outflow area in the eye. In each 
section, “total length” of the TM (TL) and “filtration length” of TM containing tracer (FL) were 
quantified. Percent effective filtration length (PEFL = FL/TL * 100%) was subsequently 
calculated as performed in previous studies (Figure 3)
24, 28. Tracer-containing TM was only 
included in the measurement if the fluorescence created a clear banded pattern and if confocal 
microscopy confirmed microbead deposition along the JCT and inner wall of Schlemm’s canal; 
irregular, hazy points of fluorescence were not included. If a specific tissue section required two 
images, a landmark within the tissue was used to prevent measurement overlap. Overall PEFL 
for the entire eye was calculated by averaging all PEFL measurements. A masked second 
investigator reviewed the quantification process to ensure its validity (n=10 images). If any 
disagreement arose, a third party would determine the accuracy of the calculations. The 
investigators would then review the data points in question together and identify the reason for 
the discrepancy in order to prevent future disagreements. Statistical analyses comparing PEFL 
and IOP of WT and SPARC KO mice were completed using a 2-tailed paired Student’s t-test. 
Correlation between PEFL and IOP and the associated coefficient of determination (R
2 value) 
was calculated using Microsoft Excel. SAS Software (SAS, Cary, NC) was used to run a 
regression diagnostic; the Studentized Residual Test was utilized to identify any outliers within 
the linear regression data. An outlier was defined as any residual point with the standard 
deviation absolute value greater than 3. Prism 5 (GraphPad Software, La Jolla, CA) was used to 
create all graphs.  
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Light and Electron Microscopy 
  Sections containing TM and SC that displayed a high concentration of fluorescent tracer 
(“high-tracer”) or absent tracer (“low-tracer”) by confocal microscopy in both WT and KO eyes 
were then processed for light and electron microscopy. Sections were post-fixed with 2% 
osmium tetroxide (Electron Microscopy Sciences, Hatfield, PA) in 1.5% potassium ferrocyanide 
(Fischer Scientific Company, Fair Lawn, New Jersey) for 2h.  Sections were then dehydrated 
using a graded series of ethanol and subsequently embedded in Epon-Araldite mixture (Electron 
Microscopy Sciences, Hatfield, PA). Semi-thin sections (2 µm) were cut and analyzed using 
light microscopy with an Olympus BX40 microscope (Olympus, Center Valley, PA). Sections 
containing regions of interest were then prepared for electron microscopy; thin sections (90 nm) 
were produced, stained with uranyl acetate (Fischer Scientific Company, Fair Lawn, New 
Jersey), and examined using transmission electron microscopes (Phillips EM 300, Eindhoven, 
Netherlands and JEOL JEM-1011, Tokyo, Japan). Images were taken along SC at varying 
magnifications. Additional details regarding the processing can be found in previous 
publications
25.  For collagen fibril diameter measurements, EM images at x40,000 magnification 
were used.  A total of 150 fibrils counted from 5 different areas within the JCT were used to 
compute an average diameter for each subtype (i.e., WT high-tracer, WT low-tracer, etc.). Thus, 
a total of 300 fibers were counted for each eye. Only fibers that were clearly cut in cross-section 
were included, in order to ensure accurate measurement of fibril diameter. Image J (NIH, 
Bethesda, MD) was utilized to measure the collagen fibril diameter. Microsoft Excel was used to 
perform statistical analyses and Prism 5 (GraphPad Software, La Jolla, CA) was used to create 
graphs.  
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Intravitreal Injection 
Adenoviruses containing either an empty vector or an hTGFß2 mutant constructs were 
generated by Allan Shepard (Ad5.CMV.hTGFß2mut & Ad5.CMV.empty)
64. The hTGFß2 
construct was mutated at amino acids 226 and 228 to create constitutively active hTGFß2 in the 
tissue; additional details on engineering of the adenoviruses have been previously published
64. 
The mouse was anesthetized with an intraperitoneal injection of 5µL/g ketamine/xylazine 
mixture (90mg/kg ketamine + 9mg/kg xylazine; Webster Veterinary Supply, Devens, MA). After 
reaching a suitable level of anesthesia (confirmed by absence of toe-pinch reflex), the mouse was 
positioned on a mounting stage (Mouse and Neonatal Rat Adaptor). Using a 10 µl Hamilton 
microsyringe (Nanofil) connected to a 35G needle (NF35BL-2), empty (hereby referred to as 
Ad.empty) or TGFß2-containing adenovirus (hereby referred to as Ad.TGFß2) was injected into 
the intravitreal space of the right eye, just posterior to the limbus, for a final viral titer of 6 x 10
6 
pfu (1.5µL of 4 x 10
9 pfu). The volume was delivered at 4 nL/s by a microprocessor-based 
microsyringe pump controller (Micro4).  Lubricating eye drops (Nature’s Tears; Rugby 
Laboratories, Duluth, GA) were applied to the cornea to prevent dehydration during the 
injection. After completion of the injection, the needle was rapidly withdrawn, and the presence 
of the needle in the desired space was confirmed with observation of vitreous on the needle tip. 
One drop each of proparacaine 0.5% (Alcaine; Alcon, Fort Worth, TX), ofloxacin 0.3% (Akorn, 
Lake Forest, IL), and prednisolone acetate 1% (Pacific Pharma, Irvine, CA) was applied to the 
injected eye to minimize pain, risk of infection, and inflammation respectively, in accordance 
with IACUC policy. Prednisolone was necessary to prevent the formation of corneal edema; a 
pilot study demonstrated that without an anti-inflammatory, injection of either Ad.TGFß2 or 
Ad.empty led to significant corneal edema, thereby confounding IOP measurements using 
rebound tonometry (data not shown).  
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Tissue Processing & Histology 
After determining the overall IOP trend in a cohort of WT and KO mice injected with 
TGFß2 over approximately 2 weeks, the peak IOP was noted to be 8 days after injection. A 
smaller cohort of mice was subsequently injected with Ad.empty and Ad.TGFß2 for 
morphologic analysis specifically at this time point of 8 days. At that time, the mice were 
euthanatized with CO2, and their eyes were enucleated immediately for fixation in 10% formalin 
(VWR International; Radnor, PA) for 48 hours at room temperature, followed by 70% ethanol at 
4ºC. Eyes were then processed and embedded in paraffin wax for serial sectioning of 5µm-thick 
sections, which were stained with hematoxylin and eosin.  
Immunohistochemistry  
The following antibodies were utilized in this study: collagen I (600-401-103-0.1; 
Rockland, Gilbertsville, PA), collagen IV (AB756P; EMD Millipore, Billerica, MA), collagen 
VI (SAB4500387; Sigma Aldrich, St. Louis, MO), fibronectin (ab23750; Abcam, Cambridge, 
MA), laminin (AB2034; EMD Millipore), PAI-1 (ab28207; Abcam), connective tissue growth 
factor (sc-14939; Santa Cruz, Dallas, TX), SPARC (AF942; R&D Systems, Minneapolis, MN), 
TGFß2 (ab36495; Abcam). Sections were washed with xylene and subsequently hydrated with 
ethanol dilutions (100%, 95%, 70%.) Tissue was then blocked in 5% bovine serum albumin 
(when probing for fibronectin) or 10% donkey serum (all other antibodies) for 1 hour at room 
temperature. Animal serum contained fibronectin epitopes, making it incompatible with the 
fibronectin antibody. Tissue was then permeabilized using 0.2% Triton-100 and primary 
antibody was applied at 1:100 concentration overnight at 4ºC. Slides were subsequently washed 
with 1x PBS-T and 1:200 secondary antibody was applied for 1 hour at room temperature. Slides 
were washed once again, and the tissue was imaged using the Zeiss Axiovert 200M inverted  
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fluorescent microscope (Carl Zeiss; Heidelberg, Germany) attached to a digital camera 
(AxioCam MR3; Carl Zeiss). Images were obtained using the associated software (Axiovision 
4.8.2; Carl Zeiss). Slides of tissue treated with Ad.empty and Ad.TGFß2 were imaged at the 
same time using the same control slide to minimize background.  
Fluorescence Intensity Measurements 
Quantification of fluorescence was completed using previously established 
methodology
59, 87-89. Briefly, the section stained with secondary antibody only was used to 
identify optimal exposure times for target ECM proteins (Alexa Fluor 488) and TGFß2 (Alexa 
Fluor 594) that would eliminate signal due to nonspecific binding.  These exposure times were 
used to image fluorescence from target protein and TGFß2 expression in all other sections. Three 
areas within the TM were selected at random for each section, and ImageJ (NIH, Bethesda, MD) 
was used to calculate the average fluorescence in the 488 and 594 channels using a rectangular 
area of interest with consistent dimensions (w0.40 x h1.20 µm). 
Immunoblotting 
  Additional intravitreal injections with Ad.empty or Ad.TGFß2 were completed, and the 
mice were euthanized 8 days after injection (at the time of peak IOP). Eyes were enucleated and 
placed in 100µL 1X DMEM. Each globe was dissected, with the anterior segment isolated from 
the lens and posterior segment. Anterior segments were then placed in 50µL 1X 
radioimmunoprecipitation assay (RIPA) buffer with protease inhibitors and homogenized. The 
solution was centrifuged at room temperature for 5 minutes at 12,000 RPM. Supernatant was 
isolated and equal amounts of total protein were mixed with 2X SDS reducing buffer (125 mM 
of Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 0.01% bromophenol blue). Using 8%  
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All data were analyzed in Microsoft Excel (Microsoft, Redmond, WA) or Prism 6 
(GraphPad, La Jolla, CA). Two-way ANOVA with multiple comparisons followed by post hoc 
Bonferroni correction were completed to compare the three treatment groups to obtain the 
adjusted p-value. Percentage of IOP change in WT compared to KO was calculated and assessed 
for statistical significance using the 2-tailed unpaired Student’s t-test. Statistical analyses for 
immunohistochemistry data were completed using paired Student’s t-tests, as each individual 
group of tissue (i.e., WT Ad.empty, WT Ad.TGFß2, KO Ad.empty, KO Ad.TGFß2) was treated 
together, but at a separate time from other groups comprising the total sample size. Paired t-tests 
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Chapter I 
Results 
No Significant Difference in WT & KO Affinity for Microbeads 
Mean total corrected fluorescence (TCF) of microbeads binding to the TM in bathed WT 
& KO eyes did not differ, with WT TCF = 6.05 x 10
9 ± 4.37 x 10
8 and KO TCF = 6.19 x 10
9 ± 
3.67 x 10
8 at 37ºC (N=5 pairs, p=0.817; Figure 4A). Tracer was uniformly present in all regions 
of TM in both WT and KO eyes. The experiment was repeated overnight at 4ºC to assess for any 
temperature effect, which again confirmed no significant difference in TCF (WT TCF = 9.48 x 
10
9 ± 5.78 x 10
8, KO TCF = 9.59 x 10
9 ± 6.85 x 10
8; N=4 pairs, p=0.906.) Confocal microscopy 
demonstrated that microbeads mostly collected between the superficial beams within the TM in 
both WT & KO (Figure 4C). Electron microscopy also showed no significant difference in the 
microbead binding. In both tissues, tracer was observed in large, open spaces between trabecular 
beams (Figure 5). Tracer was not found within the JCT or SC. 
Lower IOPs in SPARC KO Mice 
Our results confirmed the lower IOP of SPARC KO mice, with a 22.7% reduction in the 
IOP of SPARC KO mice compared to that of WT mice. The mean WT IOP was 16.3 ± 2.4 mm 
Hg, while mean KO IOP was 12.6 ± 2.5 mm Hg (p<0.005, N=11 pairs).  
Segmental outflow in WT eyes, more continuous outflow in SPARC KO eyes 
Segmental flow was identified in both WT and SPARC KO mice, but to a much lesser 
degree in the latter (Figure 6A & B). WT mice had tracer deposition only in specific regions of 
the eye; however, there was no consistent pattern present among the WT eyes.  The deposition  
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pattern was much more continuous in KO mice. While outflow appeared almost always on the 
lateral aspects of the WT eye, outflow was more variable in the superior and inferior portions of 
the eye. Thus, it was not possible to attribute the outflow pattern to the presence of specific 
venous structures in certain regions. In contrast to data from the passive binding assay, confocal 
microscopy of high-tracer regions demonstrated the strong presence of microbeads throughout 
the TM, extending into the deeper portions of the TM along the inner wall of SC; tracer can also 
be observed within the canal (Figure 6C & D). When viewed en face, high-tracer regions often 
demonstrated the presence of microbeads within episcleral veins, reflecting the full penetration 
of microbeads through the TM, Schlemm’s canal, and into the venous system (Figure 6E). In 
contrast, low-tracer regions demonstrated minimal tracer within the TM; no microbeads were 
found in SC or episcleral veins. 
PEFL Higher in SPARC KO Mice 
Using tracer distribution as a representation of outflow distribution around the 
circumference of the eye, the increase in percentage effective filtration length (PEFL = FL/TL) 
reflects a significant increase in the area of TM utilized for outflow in the KO eye. PEFL 
significantly increased in SPARC KO mice (70.61% ± 11.36%, N=11) compared to WT mice 
(54.68% ± 9.95%, N=11, p<0.005; Figure 7). Thus, it appears as though the absence of SPARC 
significantly affects the aqueous humor outflow pattern. A sample confocal microscopy image as 
well as an estimation of FL and TL, which allows for calculation of PEFL, can be reviewed 
(Figure 3). In Figure 3A, the tracer is present in the TM overlaying the SC. Figure 3B is an en 
face view that illustrates how the total length of the TM in this section and the length covered by 
tracer were quantified. 
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IOP and PEFL are Inversely Correlated 
A negative correlation between IOP and PEFL was observed (Figure 8); PEFL decreased 
as IOP increased. This suggests that a decrease in the area of bead deposition corresponded to an 
overall decrease of outflow, linked to a relatively elevated IOP.  Conversely, greater bead 
deposition represented increased outflow of aqueous humor, which was associated with 
decreased IOP. When fit with a corresponding linear regression line, an R
2 value of 0.59 was 
calculated (N=22). However, one data point was identified as an outlier by the Studentized 
Residual Test with a standard deviation of -3.82. When this point and its matched pair were 
removed from the analysis, R
2 increased to 0.72 (N=20, p<0.0001), indicating a more robust 
association between PEFL and IOP.  
High-tracer regions display less compact morphology than low-tracer regions 
  Electron microscopy images at lower magnification (x8,000) of high-tracer and low-
tracer regions in WT and KO eyes demonstrated that high-tracer regions have less compact 
morphology (N=3 pairs; Figure 9). The JCT and TM in low-tracer images appear to be much 
more compact, with the trabecular beams layered closer together. In contrast, increased space 
between trabecular beams was noted in high-tracer samples. The difference in morphologic data 
is consistent with previous findings in other animal species
24, 28.  
Collagen fibril diameter is significantly decreased in JCT of SPARC KO mice 
No significant differences in morphology were detected between the TM of WT and KO 
tissues at the light microscopy level (data not shown), consistent with our previously published 
report
58; the iridocorneal angles were indistinguishable with the same level of cellularity and 
sizes of various structures. At higher magnification electron microscopy (x40,000), collagen  
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fibril diameter within the JCT was found to be significantly decreased in SPARC KO mice 
(28.272 nm) compared to WT mice (34.961 nm, p<0.0005, N=3 pairs; Figure 10). If 
differentiated into high-tracer vs. low-tracer regions of WT & KO tissue, collagen fibril diameter 
was significantly decreased in both high-tracer regions of KO tissue compared to that of WT 
(27.232 nm and 35.459 nm respectively, p<0.0005) and in low-tracer regions of KO vs. WT 
(29.312 nm and 34.462 nm respectively, p<0.0005). 
Microbeads were also found in the open spaces of the JCT in high-tracer regions at this 
higher magnification (Figure 11). Microbeads were not identifiable in the JCT of low-tracer 
regions, a consistent finding given its more compact extracellular matrix (Figure 9). More tracer 
was also found in the JCT regions facing the collector channel ostia, beneath the gaps amongst 
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Discussion 
Our results contribute new data to the field while confirming previous results. This study 
was novel in discovering the presence of segmental flow in the mouse species, which had not 
been previously demonstrated. This finding is unique also because of its evolutionary 
implication. Since segmental outflow has been observed in the human, monkey, bovine eyes, and 
now the distant rodent of the mouse, the segmental pattern of outflow may be strongly conserved 
amongst mammalian species. This is the first observation of segmental flow in a small mammal. 
We were unable to assess a potentially dynamic nature to flow patterns (i.e., changes from high-
tracer to low-tracer states) due to our inability to assess outflow in each eye more than once. It is 
possible that changes could occur due to alterations in positioning of the eye. The impact of 
gravity on outflow should be considered here as well. 
Our results also demonstrate a significant increase in PEFL in SPARC KO mice, with an 
overall change from segmental to more continuous outflow. These results were reproducible in 
the large sample size that was utilized. With these data corroborating our lab’s previous findings 
regarding the significant decrease in IOP of the KO mouse, this study confirms the influence of 
SPARC on outflow and creates the basis for a relationship between ECM, filtration area, and 
IOP. The association between the PEFL and IOP was reasonably strong with an R
2 value of 0.59, 
even in the presence of an outlier. When this point was removed, the R
2 value increased to 0.72, 
reflecting a strong correlation. With the increase in PEFL of KO eyes and this association, 
SPARC appears to be an important modulator of aqueous humor outflow and IOP in mice. In the 
absence of SPARC, IOP decreases and PEFL increases significantly due to increased outflow 
observed throughout the entire TM. While correlation does not imply causation, we would still 
postulate that the lack of SPARC leads to the increase in PEFL, and this increase in overall  
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outflow is what causes the reduction in IOP. The observed increase in PEFL could be due to a 
fundamental difference in the ECM composition caused by the lack of SPARC.  Again, this is a 
suggestion based on the results of this study; further investigation is warranted in order to 
establish this causal relationship. For example, studying any association between SPARC and 
collagen IV or fibronectin may be of value in investigating how SPARC directly impacts ECM 
levels. Collagen IV would be of particular interest due to the presence of a basement membrane 
between the JCT region and Schlemm’s canal, which may impact outflow resistance. The 
validity of such a relationship appears to be greater due to the results of these experiments.  
The electron microscopy images that were obtained provide valuable insight into the 
structural basis of the observed segmental outflow. Light microscopy in this study and a previous 
publication demonstrated that there were no gross differences between WT and SPARC KO eyes 
that might influence outflow pathways (e.g., globe size, lens size, iris thickness, or iridocorneal 
angle degree)
58. However, utilizing electron microscopy, differences in tracer distribution could 
be attributed to the compactness of the TM; the less compact the tissue, the greater the outflow of 
aqueous humor, and the greater the amount of tracer in this region. In contrast, the compact TM 
inhibited outflow, leading to a minimal amount of tracer in these areas. These structural data 
corroborate the concept of segmental flow; aqueous humor tends to leave the eye in specific 
areas depending on the compactness of the TM.  
The significant difference in collagen fibril diameter within the JCT of WT & KO tissues 
reflects the role of SPARC in ECM processing. Significant changes in collagen fibril diameter in 
other tissues of SPARC-null mice have been reported in previous studies
47, 48. Bradshaw et al. 
showed that dermal collagen fibrils in SPARC KO mice were significantly smaller and more 
uniform compared to that of WT mice. They also demonstrated that SPARC was essential to the  
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maturation of collagen fibers in the dermis, highlighting the effect of SPARC on collagen 
processing and ECM composition.  
In the trabecular meshwork, our data suggests a potential mechanism by which IOP is 
reduced in SPARC KO mice. With a significant change in collagen fibril diameter, more of the 
TM is converted into a high-tracer (i.e., less compact) state, which increases outflow as reflected 
by the PEFL data in this study. This subsequently leads to a decrease in IOP. In contrast, the 
glaucomatous eye may present increased SPARC expression, reversing these values and leading 
to increased IOP. Again, we should emphasize that this is a postulated hypothesis of how 
SPARC may be involved in glaucoma. In addition, the precise relationship between collagen 
fibril diameter and IOP is unclear. Our group previously reported a decrease in IOP but increased 
JCT collagen fibril diameter in thrombospondin-1 and 2 (TSP1 & 2) knockout mice
90. It seems 
as though the deletion of matricellular proteins affects post-translational processing of 
collagens
91. Fibril diameter is regulated by various processes such as crosslinking alteration by 
crosslinking enzymes (lysyl oxidase, tenascin-X, perlecan) and small leucine-rich proteoglycans 
(decorin, biglycan, fibromodulin), cleavage of procollagen by proteinases, organization of fibril 
assembly by fibronectin and integrins, and nucleation by collagen V and XI
92, 93. SPARC may be 
involved in modulating one or more of these processes.  
It is also possible that SPARC affects the quality of the ECM in the TM, and not 
necessarily the ultrastructural anatomy. Previous studies have indicated that it is not just the 
quantity of the ECM, which would be appreciated through electron microscopy, but the quality 
of the ECM that dictates outflow
94. In addition, it is possible that the lack of SPARC leads to a 
decreased amount of compact TM, thereby leading to greater PEFL. The difference may not lie 
in the morphology itself, but rather how much of the entire TM is densely compact. Additional  
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studies analyzing the entire TM tissue of a WT and KO mouse eye would be necessary to verify 
this theory, as evaluating a few samples slides would not provide sufficient data.  
Our quantification of PEFL in this experimental model system confers two significant 
advantages. First, the animal model used was genetically manipulated, leading to an endogenous 
change in physiologic outflow. This is in contrast to other current models, which often involve 
enucleated, live eyes or eyes that have artificially impaired outflow induced by laser trauma. 
Second, this model takes advantage of in vivo outflow mechanisms in the mouse to study the 
spread of the fluorescent tracer. The natural flow of the aqueous humor itself leads to distribution 
of the tracer rather than artificial perfusion; the mouse eye is still producing aqueous humor 
during the experiment and pressure gradients are still maintained. Again, this is in contrast to 
previously published studies, in which live human eyes are perfused at a controlled rate. 
Naturally there are certain limitations to this study, which we attempted to minimize as 
much as possible. One potential issue was artifact in tracer distribution due to gravity. During the 
experiments, the mouse eye was positioned as horizontally as possible (i.e., plane of the iris was 
parallel to the table). Other limitations include the inability to monitor IOP during the injection 
using a probe placed into the anterior chamber through a second insertion site. This was not 
possible due to the small size of the mouse eye; however, we attempted to minimize an IOP 
spike by using a slow infusion rate. Another potential concern was a large increase in IOP during 
the injection experiments, leading to artifact or tissue damage. An injection rate of 4 nL/s was 
chosen based on similar rates utilized in established studies evaluating fluorescent tracer 
distribution
29, 30. However, a transient elevation of IOP may have occurred during the injection 
phase, given the injection rate was slightly elevated in comparison to the endogenous aqueous 
humor formation rate (0.14–0.18 µL/min)
95, 96. Any such IOP elevation could have affected  
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tracer distribution. Given a potential difference in outflow facility between WT and SPARC-null 
eyes
58, the magnitude of IOP elevation might have differed between the two strains. Thus, the 
contrast in tracer distribution between WT and SPARC-null eyes could have been influenced by 
this potential difference in outflow facility, in addition to baseline IOP. We were unable to 
separate these factors given our experimental design. However, the differences in tracer 
distribution are still due to inherent differences between WT and SPARC-null eyes. We also 
were only able to inject the right eye of each mouse due to constraints of the experimental setup. 
However, we have no reason to suspect that outflow pathways would differ between right and 
left eyes. In addition, the right eye was consistently used in both WT and KO mice. 
Another concern raised was regarding the use of rebound tonometry for IOP 
measurement. Since SPARC influences ECM production, one could argue that the 
biomechanical properties of the cornea could have been affected, leading to abnormal rebound 
tonometer readings. This criticism has been addressed in a previous publication
58, in which 
rebound tonometer readings in SPARC KO mice were validated across a wide range of IOPs 
using direct manometry, which is not sensitive to corneal biomechanics. Furthermore, central 
corneal thickness (CCT), which could be potentially affected by the lack of SPARC, can affect 
rebound tonometry measurements. However, Haddadin et al. again demonstrated that no 
significant difference existed between the CCT of SPARC KO and WT mice, thereby 
eliminating this issue as a confounder in IOP measurements
58. One study demonstrated that there 
was near perfect agreement between TonoLab rebound tonometry and manometry in both wild-
type and glaucoma model mice
97. This methodology has gained wide acceptance in the glaucoma 
research community.  
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As mentioned above, certain techniques utilized were challenging due to the precise 
positioning of the needle required within the anterior chamber. The needle could not make 
contact with the lens or iris, as this would cause abnormal distribution of the tracer; the 
microbeads could settle within a nick in the lens, thereby reducing the effective tracer 
concentration reaching the TM. Similarly, damaging the iris would have created an artificial 
pathway for the microbeads to exit the anterior chamber.  
The injection technique had to be altered several times in order to surmount multiple 
technical challenges. First was determining the route of tracer injection. An intracameral 
injection allowed for even distribution of the tracer, while an intravitreal injection would not 
ensure consistent distribution of tracer into the aqueous humor between experiments. Since an 
even distribution throughout the TM was critical to this study, intracameral injection was chosen. 
However, leakage from this injection had to be minimized, leading to the exploration of various 
techniques. A 35G metal needle and a 100-µm silanized glass needle were used in experiments 
in order to compare the amount of leakage observed. There had been anecdotal reports that 
leakage would be further reduced with the glass needle due to silanization. However, significant 
leakage was observed with both methodologies. We decided to utilize the metal needle due to the 
technical ease. We subsequently needed to decide whether to keep the needle in the eye after the 
injection was complete and the incubation period had begun. Since significant leakage was 
observed upon retraction of the needle, the idea of keeping the needle in the anterior chamber for 
the entire incubation period was explored. Since this would involve exposing the eye to the air 
for an extended period of time, lubricating drops were applied.  
The next obstacle encountered was abnormal morphology of the TM due to retrograde 
flow of blood from the episcleral veins into SC. This occurred when the needle was removed  
  35 
after the incubation period. The reflux flow led to dilation of SC and compression of the TM in 
some eyes, thereby precluding any useful morphologic analyses. The injection protocol was 
initially altered by loading the syringe with tracer and KII fixative separated by mineral oil. 
However, this technique failed due to the miscibility of these compounds. We then decided to 
separate the microbead tracer and fixative with a miniscule air bubble. After consulting multiple 
experts, it was determined that the injection time was a relatively short period of time, 
insufficient to cause any oxidative damage to the tissue that might confound the microscopy 
work. This technique was successfully utilized in maintaining TM anatomy. 
The lateral canthotomy method was used instead of traditional methods during 
enucleation, as no direct pressure was placed on the globe, which could potentially disturb TM 
morphology or tracer distribution. One unavoidable, potential source of artifact was the pressure 
applied to the eyeball when inserting the needle into the anterior chamber. Forceps are used to 
grasp the eyeball during insertion in order to stabilize the eye, which might have increased 
external pressure thereby affecting TM and SC morphology. However, this step was 
unavoidable, as the eye had to be immobilized to introduce the needle into the anterior chamber. 
Both groups were equally exposed to this initial pressure.  
The overall fragility of the mouse eye in comparison to that of other species may have 
contributed to the difficulties encountered with TM morphology as well. The TM was often 
destroyed while removing the iris during initial experiments. The iris was no longer removed 
after this was discovered. We also found that the iris auto-fluoresced at the same wavelength of 
the tracer, leading to some image artifact. However, the unique pattern of tracer within the TM 
was quickly recognized, which eased our ability to identify and disregard artifact from the iris.  
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The microbead injection technique has been validated and utilized by various other 
groups
24, 28. As previously discussed, Zhang et al. and Lu et al. used similar tracer microbeads in 
their studies with monkey and bovine eyes respectively, validating the use of the microsphere 
technique in studying outflow and outflow resistance. In these studies as well as our work, the 
microbeads remained in the TM and SC, instead of being washed out, at the time of evaluation. 
A time-scale experiment was initially conducted in order to determine the optimal incubation 
time, which was discovered to be 45 minutes; any less time led to the lack of significant tracer in 
the TM, while additional time led to the tracer being washed out into the episcleral veins. Thus, 
with this careful determination of the incubation time, we believe that our tracer data is not a 











  37 
Chapter II 
Results 
IOP Stable Under Isoflurane Anesthesia 
Under isoflurane anesthesia, IOP measurements were consistent and stable between 
minutes 5 and 8 (Figure 12). The difference of IOP between WT and SPARC KO mice was 
reproducible at all time points (p<0.05 at all points; N=8). Mean WT IOP during minutes 5 to 8 
was 16.5 ± 2.5 mmHg, while mean KO IOP was 12.4 ± 1.1 mmHg (p=0.0057). The mean 
percentage IOP decrease in KO eyes was 24.6 ± 0.7%. 
Immunoblotting Confirmation of TGFß2 infection 
  Infection of the TM by TGFß2 was verified with immunoblotting (Figure 13). TGFß2 
was significantly increased in both WT and KO eyes treated with Ad.TGFß2 compared to eyes 
treated with Ad.empty (N=4/group, p=0.0023 and p=0.0141 respectively). There was no 
significant difference in TGFß2 expression levels between WT and KO Ad.empty-injected eyes 
(p=0.7293). SPARC was also noted to increase significantly in WT tissue by 56.2% with 
Ad.TGFß2 infection (p=0.0425).  
IOP Elevation with TGFß2 in WT mice but not SPARC KO mice 
In WT mice, a significant difference in IOPs between the Ad.TGFß2-injected and Ad.empty-
injected eyes, and between the Ad.TGFß2-injected and uninjected contralateral eyes was 
detected (p<0.0001) (Figure 14). Ad.TGFß2-injected WT mice had an increase of IOP at the 
fourth day after injection (Day 4), Day 6, Day 8, and Day 11 when compared to the Ad.empty-
injected WT mice (p=0.0166, 0.0230, <0.0001, 0.0230 respectively; Figure 14). When compared  
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to the IOPs of uninjected contralateral eyes, Ad.TGFß2-injected eyes had a significant increase 
during the same period, but the Ad.empty-injected WT eyes had no significant increase 
compared to uninjected contralateral eyes (Table 1).   
A difference in IOP was also observed amongst the treatment groups in KO mice 
(p=0.0023). However, in contrast to WT mice, Ad.TGFß2-injected KO mice had a mild elevation 
in IOP that was not significant compared to Ad.empty-injected KO mice (Figure 14 & Table 1). 
If Ad.TGFß2-injected KO eyes were compared to uninjected contralateral eyes, the change in 
IOP became statistically significant only at Day 8 (p=0.0385).   
The peak of IOP increase was noted to be at Day 8 for both WT and KO eyes. At this 
time, the average IOP of Ad.empty-injected WT IOP was 14.3 mmHg, Ad.TGFß2-injected WT 
IOP 18.3 mmHg (p<0.0001), Ad.empty-injected SPARC-null IOP 12.1 mmHg, and Ad.TGFß2-
injected SPARC-null IOP 13.0 mmHg (p=0.7518).  
The difference in percentage of IOP increase between WT and SPARC-null eyes was 
significant at Days 4, 6, and 8. At Day 8, the percentage increase of IOP from baseline was 28.5 
± 4.2% in WT mice and 14.4 ± 4.9% in KO mice (p=0.0444, N=8; Figure 15). 
No Change in Angle Morphology 
No significant difference was observed between all 4 experimental groups on light 
microscopy (Figure 16). In contrast to previous findings regarding TGFß2 injection in mice
64, 
the iridocorneal angle remained open in all groups. No synechiae were observed in the anterior 
chamber. 
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Confirmation of TGFß2 infection 
Immunohistochemistry was performed on whole eyes to demonstrate tissues infected by 
Ad.TGFß2. Injected mice were sacrificed at peak IOP, 8 days after adenoviral injection. WT and 
KO eyes that were uninjected, injected with Ad.empty, or injected with Ad.TGFß2 were 
sectioned and stained for TGFß2 (Figure 17). TGFß2 staining was similar between uninjected 
and Ad.empty-injected eyes in both WT and KO tissue. Staining was strongly increased in 
Ad.TGFß2-injected eyes on Day 8, specifically in the retina, vitreous humor, and trabecular 
meshwork. Additional Ad.TGFß2-injected mice were sacrificed on Day 13 and their eyes were 
stained for TGFß2 to demonstrate a reduction in TGFß2 expression to levels similar to 
Ad.empty-injected eyes. 
IHC demonstrates importance of Collagen IV and Fibronectin 
Upon TGFß2 stimulation in WT mice, the fluorescence intensity collagen IV, fibronectin, PAI-1, 
connective tissue growth factor (CTGF), and SPARC were noted to significantly increase 8 days 
after injection compared to WT mice injected with Ad.empty (p<0.05, N=3; Figures 18-20).  
Collagen I and laminin intensities were also noted to increase, but were not significant. No 
change was noted in collagen VI levels. When assessing the fluorescence of the same proteins in 
KO mice 8 days after injection, only the intensities of PAI-1 and CTGF significantly increased 
with injection of Ad.TGFß2 vs. Ad.empty (p<0.05, N=3; Figures 18-20). The collagen IV and 
fibronectin increase observed in WT mice was attenuated in KO mice and did not achieve 
statistical significance (Table 2).  
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Discussion 
  Based on our intravitreal injection data, SPARC appears to have a key role in TGFß2-
mediated ocular hypertension. When compared to eyes injected with Ad.empty, Ad.TGFß2-
injected KO eyes demonstrated no significant elevation in IOP. In contrast, the IOP of WT eyes 
injected with Ad.TGFß2 increased significantly. When compared to the contralateral uninjected 
eyes, Ad.TGFß2-injected KO mice have a substantial delay of IOP elevation (significant at only 
one time point, Day 8), a blunting of the magnitude of increase, and shortening of the increase to 
only one time point.  The failure to completely inhibit the IOP response in Ad.TGFß2-injected 
KO mice likely represents redundancy amongst matricellular proteins. SPARC, 
thrombospondins-1 and -2, tenascins-C and -X, hevin, and osteopontin have all been shown to 
have important roles in affecting ECM assembly, MMP activation, and collagen fibrillogenesis
56, 
90, 98. In addition, TGFß2 is also thought to act through other pathways, such as inducing TM cell 
senescence or altering the actin cytoskeleton
78, 99, 100. It is likely that these pathways are still 
active with TGFß2 injection in the SPARC KO mouse.  
Our results seem to confirm the previously reported increase in PAI-1 and fibronectin in 
Ad.TGFß2-injected mice
64. We also observed an increase of CTGF and collagen IV 
fluorescence. Shepard et al. found an increase, albeit non-significant, in the mRNA levels of 
these proteins. However, mRNA levels do not necessarily correlate with protein expression, as 
changes in protein levels could result from mechanisms other than an increase in transcription 
and translation, such as decreased turnover. We have previously observed this phenomenon with 
SPARC-induced changes in JCT ECM
59. Increases of PAI-1 and CTGF, which have been 
observed in perfused human anterior segments
71, appear to be mediated by mechanisms other 
than SPARC. CTGF and PAI-1 are often regulated in a similar fashion; both have been shown to  
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increase in TM cells after TGFß2 stimulation
62, 101. The elevated levels of PAI-1 in POAG 
patients and its function in decreasing ECM turnover by inhibiting MMPs underscores the role of 
ECM dysregulation in glaucoma pathogenesis
102, 103.  
Both immunohistochemistry and immunoblot demonstrated an increase of SPARC 
following TGFß2 stimulation
77. As previously discussed, SPARC overexpression increased 
collagen IV and fibronectin within the JCT TM in perfused human anterior segments
59,  
illustrating conservation of function between humans and mice. TGFß2 overexpression in mice 
caused increases in collagen I and laminin that did not reach statistical significance, which was 
also observed in perfused human anterior segments
59. However, it appears as though some 
effects are species-specific, as collagen VI was noted to increase with SPARC overexpression in 
human tissue, but not in TGFß2-stimulated mice.  
Collagen IV and fibronectin are significant components of the JCT basal laminae. 
SPARC stimulates the partial unfolding of fibronectin, which is crucial to overall ECM 
assembly
45, 104, and is essential to collagen IV deposition
105, 106. Thus, the deletion of SPARC 
would be expected to impact basal lamina homeostasis. It is possible that without SPARC, the 
attenuation of the collagen IV and fibronectin upregulation is significant enough to reduce 
outflow resistance, and blunt the TGFß2-mediated IOP increase. In addition, we have previously 
shown that in perfused human anterior segments, SPARC overexpression decreases MMP-9 
activity, thereby attenuating ECM degradation
59. We could surmise that SPARC moderates 
MMP activity, and that MMP activity is higher in the SPARC-null mouse, leading to greater 
ECM degradation and a diminished IOP increase. While CTGF and PAI-1 have been shown to 
be important contributors to ECM synthesis and degradation respectively, they have not been 
shown to interact with SPARC. The lack of change in their levels in TGFß2-injected SPARC- 
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null mice seems to suggest that they may work through SPARC-independent pathways to 
modulate ECM protein expression and MMP activity. We also demonstrated that IOP remains 
stable in mice between minutes 5 and 8. To our knowledge, this is the first time-course study 
corroborating the stability of IOP measurements with an inhaled anesthetic in mice; a similar 
study was conducted in Brown Norway rats
107. We chose the 5 to 8-minute period because it was 
early enough to ensure corneal dehydration would not become an active issue and the earliest 
point at which IOP reached a stable plateau. These data serve as an important confirmation of 
technique, given the increased utilization of the mouse model in aqueous outflow studies 
involving IOP measurement.  
We also confirmed that a significant IOP decrease in SPARC KO mice compared to that 
of WT mice was reproducible under isoflurane anesthesia. Our group previously reported a 15-
20% IOP decrease in KO mice anesthetized with ketamine/xylazine
58. Given that inhaled 
anesthetics are generally known to reduce IOP
107-109, an absolute decrease in IOP values with 
isoflurane compared to those obtained with ketamine would be expected and was observed. The 
greater decrease in percentage of baseline IOP (approximately 24%) may simply be normal 
variability, as we previously found a 22.7% IOP decrease in SPARC KO mice as detailed in 
Chapter I of this work and elsewhere
110. Conversely, this percentage change could also be related 
to the difference in metabolism of isoflurane and ketamine. While ketamine is metabolized by 
CYP3A4 in the liver
111, isoflurane undergoes minimal hepatic metabolism and is primarily 
cleared by respiration
112, 113. Given the known role of SPARC in both ECM assembly and 
dissolution in the lung
114, 115, it is possible that SPARC KO mice are unable to clear the 
compound as easily as WT mice, thereby leading to a higher serum concentration and additional 
impact on IOP.   
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  There were multiple challenges encountered during these experiments. It should be noted 
that aside from probing for SPARC, immunohistochemistry findings were not corroborated with 
other forms of molecular analysis due to the difficulty of observing subtle changes in ECM 
protein expression specifically within the mouse TM. Isolation of mouse TM from cornea and 
iris is quite challenging, as the TM is fragile and often detaches with the iris or cornea. 
Invariably, there is contamination by adjacent tissues such as the iris and choroid. We believe 
that the elevation in SPARC detected by immunoblot of anterior segments was possible due to 
SPARC being the most highly upregulated protein with TGFß2 stimulation
62. Other ECM 
proteins are not nearly as highly upregulated as SPARC, making any increase in expression 
within the TM difficult to observe by molecular analyses.  
There were differences in both methodology and results with TGFß2 overexpression 
compared to a previous study
64. First, we used a lower viral titer of 6 x 10
6 pfu instead of 6 x 10
7 
pfu. In initial studies, a higher titer caused corneal edema as early as one day after injection that 
could not be prevented with steroid treatment and led to significant artifact when measuring IOP 
with rebound tonometry. This was a significant challenge in this study; multiple studies were 
completed using different viral titers with and without topical prednisolone to identify the 
optimal titer that would induce IOP elevation without corneal inflammation. We also considered 
resynthesizing the adenoviral vector in order to ensure there were no other confounding causes of 
the edema (e.g., degradation products inciting an inflammatory reaction). We ultimately found 
that 6 x 10
6 pfu was the highest viral titer that led to IOP elevation without corneal edema when 
one drop of prednisolone was applied after injection. It is unlikely that the IOP elevations 
observed in our study were a corticosteroid-mediated response from the single topically applied 
drop containing approximately 30 µg of prednisolone acetate.  Even assuming intraocular  
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penetration of 100% of the available drug contained within a 30 µL drop.  In humans, the tear 
film and conjunctival cul-de-sac can only hold approximately 30 microliters from a topically 
applied drop
116. Although the equivalent volumes are unknown in a mouse, it can be safely 
assumed to be much smaller given the difference in globe size between humans and mice.  
Corticosteroids require chronic treatment to raise IOP
117. In mice, there is only a minimal change 
in IOP even with a subconjunctival dose of 800 µg of triamcinolone
118. In addition, our lab 
previously demonstrated that topical prednisolone acetate applied four times daily to the mouse 
eye does not induce an IOP increase even after 3 weeks (unpublished data). 
The difference in mouse strain and age may explain the lower magnitude of IOP increase 
in our Ad.TGFß2-injected mice, the mild variation of IOP observed in uninjected eyes, and the 
shorter duration of IOP elevation compared to Shepard et al
64. The duration of IOP elevation was 
limited, consistent with the natural decay of foreign genetic material within a mammalian cell of 
5-12 days
119, 120. Adenoviral-delivered plasmids remain for approximately 14 days in murine eye 
tissue
121, 122. However, other studies have demonstrated that adenovirus can last up to 4 weeks
64, 
123-125. Animals used in those studies were often older and of different strains, and viral titers 
were higher; we might have observed a more sustained response if a higher viral titer had been 
used. Immunohistochemistry completed in our study showed that TGFß2 synthesis was 
attenuated at Day 13 (Figure 17), corroborating our IOP data and illustrating the time course of 
infection using this particular viral titer in this mouse species. In contrast to the work of Shepard 
et al., our Ad.TGFß2-injected eyes did not display angle closure, which would elevate IOP
64. 
The slightly lower viral titer and one-time application of prednisolone could have mitigated the 
formation of synechiae and subsequent angle closure. Even empty adenovirus has been shown to 
cause a modest anterior chamber inflammation
64; the prednisolone may have sufficiently reduced 
such inflammation to prevent angle closure.   
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Conclusions and Suggestions for Future Work 
This work provides strong evidence implicating SPARC in the regulation of IOP and 
aqueous humor outflow, further defining the potential role of this protein in glaucoma 
pathogenesis. Our work demonstrates for the first time that segmental flow exists in the mouse, 
which was previously unclear amongst the glaucoma TM community. This finding may reflect 
the importance of segmental flow in mammalian homeostasis, given its strong conservation from 
the mouse to the human. In addition, this study is novel in its methodology, utilizing an in vivo 
injection system to examine one specific endogenous protein and its effect on outflow and IOP. 
Due to the role of SPARC in ECM synthesis and degradation, our data provides even further 
support to the theory that ECM within the TM influences the degree of outflow resistance (i.e., a 
reduced amount of ECM is equated with reduced outflow resistance). In addition, an inverse 
correlation between outflow and IOP was identified. The electron microscopy data provides 
structure-function correlation, indicating that the compactness of the TM tissue affects the degree 
of outflow, and that SPARC appears to affect collagen fibrillogenesis. By implicating SPARC, 
our data associates three essential components in glaucoma pathogenesis – the molecular state of 
the ECM in the TM, the hydrodynamic process of outflow, and the clinical measurement of IOP.  
We have also demonstrated that SPARC is essential to modulating TGFß2-mediated 
ocular hypertension in mice, given the minimal redundancy with other matricellular proteins as 
demonstrated by this study. This finding is consistent with SPARC being the most upregulated 
protein with TGFß2 stimulation
62. Immunohistochemistry suggests that collagen IV and 
fibronectin levels, which appear to be SPARC-dependent, are vital to the TGFß2-mediated IOP 
increase. Given our knowledge of the synergistic role of the SC fenestrated basement membrane 
in outflow resistance, it is unsurprising that these specific proteins are involved. Since TGFß2  
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has been strongly implicated in the pathogenesis of POAG, SPARC itself may play a role in 
glaucoma pathogenesis; it may serve as a critical node in this process, mediated by various 
intracellular pathways previously described. We have also shown that IOP can be accurately and 
consistently measured in mice with rebound tonometry under isoflurane, a commonly used 
anesthetic in glaucoma mice models.  
Future work includes evaluating whether the outflow-IOP association can be shown to be 
a causal relationship. Additionally, conducting molecular analyses to understand the mechanisms 
by which the TGFß2-mediated ocular hypertensive phenotype is inhibited in the SPARC-null 
mouse would be valuable. Attempting to determine how SPARC mediates ECM levels from a 
mechanistic perspective (e.g., via integrin activation, binding to MMPs or TIMPs) would be 
helpful while studying how SPARC may be involved in glaucoma pathogenesis. From an 
engineering perspective, it would be highly valuable to the field to identify a technique that 
would allow in vivo visualization of segmental flow; this could have significant implications in 
the research community as well as in clinical practice. Finally, attempting to inhibit SPARC 
through small molecule inhibitors or viral vectors would provide insight into SPARC as a 






  47 
Summary 
  Glaucoma is a painless eye disease affecting millions of individuals across the world as 
the leading cause of irreversible blindness. The most common and only modifiable risk factor for 
developing glaucoma is elevated IOP, which is thought to be caused by impaired outflow of the 
aqueous humor. The reduction in outflow is thought to be due to dysfunction of the TM. ECM is 
an important component of the TM, surrounding and interacting with cells. SPARC, a protein 
that has been shown to modulate ECM in various tissues throughout the body, is strongly present 
in the TM, making it a point of interest in glaucoma research. Mice lacking SPARC have been 
shown to have a significantly lower IOP (approximately 15-20%). This suggests that a decreased 
amount of ECM in the TM leads to increased outflow and a lower IOP. SPARC has also been 
shown to be highly upregulated by TGFß2, an essential molecule that is elevated in the aqueous 
humor of glaucoma patients and causes ECM deposition within the TM in rodents, thereby 
leading to IOP elevation. Our first study explored the differences in outflow between WT and 
SPARC KO mice and whether outflow is linked with IOP. Our second study evaluated whether 
SPARC is an essential node in TGFß2-mediated ocular hypertension.  
  In the first study, fluorescent microbeads were used as a tracer to identify where outflow 
was occurring throughout the mouse eye; the presence of tracer in a specific region of the eye 
was interpreted as the presence of outflow in that region. A needle was placed into the frontal 
portion of the eye and the tracer was subsequently injected into the eye. After 45 minutes, the 
animal was sacrificed and the eye was removed. The eye tissue was then mounted out on a 
microscopic slide for further evaluation using confocal microscopy. The tissue was processed 
further for analysis with light and electron microscopy.   
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  In the second study, adenovirus containing a gene insert that codes for TGFß2 or no gene 
insert (the control group) was injected into WT and mice lacking SPARC. IOPs were measured 
every other day for approximately 2 weeks. Some mice that were injected with the adenoviruses 
were then sacrificed, and the eye tissue was evaluated with immunofluorescence to determine the 
relative levels of protein concentration. 
  In eyes lacking SPARC, outflow was much more homogeneous than what was observed 
in WT eyes. Quantifying the area utilized for outflow, we determined that approximately 71% of 
the total area available for outflow was utilized by SPARC-null mice, while 55% of the total area 
available was used in wild-type mice. Outflow was much more continuous in the SPARC-null 
eye when examining the overall tracer pattern. Wild-type eyes displayed segmental flow, or flow 
that was punctuated in specific regions of the eye. When evaluating the association between 
outflow area and IOPs, a strong negative correlation was discovered (R
2 = 0.72). If a mouse’s 
IOP was lower, its outflow area was greater. The electron microscopy data demonstrated that the 
less compact the TM tissue, the easier it was for the aqueous humor to exit the eye. Eyes lacking 
SPARC were also found to have smaller collagen fibrils, demonstrating that SPARC is important 
in ECM synthesis. 
  When TGFß2 was injected into WT eyes, IOP increased significantly for approximately 
two weeks. However, when TGFß2 was injected into SPARC-null eyes, IOP did not change 
significantly. Evaluation of injected tissue showed that 4 proteins were strongly elevated in WT 
eyes. However, only two of these were significantly elevated in injected SPARC-null eyes. 
Collagen IV and fibronectin were the two proteins that did not change, seeming to indicate that 
these two proteins are important in causing IOP elevation.  
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  Our study demonstrates that SPARC plays an important role in modulating aqueous 
humor outflow, affecting the amount of TM utilized for outflow and IOP as well. Because of the 
role of SPARC in ECM modulation, this study implicates altered ECM morphology and 
compactness in the elevation of IOP. In addition, the discovery of various degrees of outflow 
throughout the mouse eye is a novel finding, underscoring its potential importance in mammalian 
evolution. The correlation data linking outflow area to IOP values is the first of its kind, 
indicating the strong relationship between the two. The second set of experiments demonstrated 
that SPARC is essential to TGFß2-mediated IOP elevation. Collagen IV and fibronectin appear 
to be essential to that process. Ultimately, this work highlights SPARC as an essential candidate 
for additional evaluation in glaucoma pathogenesis. 
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Figures and Tables 
Note: Figures 3-11 are reproduced from a previous publication
110. The Association for Research in Vision and 
Ophthalmology, the copyright holder, has granted permission for their reproduction. 
 
Figure 1. Diagram displaying the iridocorneal angle formed between the iris and cornea. Aqueous humor is 
produced by the ciliary body, after which the aqueous enters the anterior chamber and exits either via the 














Figure 2. Schematic of the conventional outflow pathway. Arrows indicate the direction of aqueous flow. The fluid 
moves from the anterior chamber into the trabecular meshwork (TM), through the cells and extracellular matrix 
(green) of the juxtacanalicular tissue (JCT), into Schlemm’s canal (SC) via the inner wall (IW), into collector 
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     (A)                (B) 
Figure 3. Sample WT image of: (A) confocal microscopy with a radial section. Schlemm’s canal (SC), trabecular 
meshwork (TM), and ciliary body (CB) are labeled. Cells have been stained with the blue TO-PRO-3 dye, while the 
fluorescent microspheres are green. (B) FL (blue) and TL (red) measurements from the en face image. In terms of 
orientation, the tissue in (A) is being viewed on the orthogonal in (B). PEFL for this specific tissue section can be 
calculated from FL and TL (here, PEFL = 868.30/1196.18 * 100% = 72.59%.) The fluorescence seen in the iris and 
ciliary body (CB) is due to auto-fluorescence. Tracer can also be seen in the scleral vein, indicating that the 











Scleral vein  
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             (C)                       (D) 
Figure 4. Representative en face images of (A) WT and (B) KO eyes bathed in the microbead solution. Due to the 
significant amount of background from tracer binding the cornea and sclera, the central and peripheral portions of 
the images were removed. (C, D) Frontal confocal sections of WT and KO tissue, respectively, with sclera, 
trabecular meshwork (TM), Schlemm’s canal (SC), and ciliary body (CB) labeled. Tracer accumulates mostly 
among the superficial–intermediate portions of the TM, rarely approaching SC. 
(A)  (B)  
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Figure 5. (A, B) Electron microscopy of WT tissue TM with Schlemm’s canal (SC), juxtacanalicular connective 
tissue (JCT), and intertrabecular space (ITS) labeled. The black box region in (A) is magnified in (B). Microbeads 
(*) were found in the open spaces within the ITS. (C, D) Electron microscopy of KO tissue TM with SC, JCT, and 
ITS labeled. The black box region in (C) is magnified in (D). Microbeads (*) were again found in open spaces 
between trabecular beams. 
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Figure 6. (A, B) Representative pair of matched WT and KO eyes. Confocal microscopy was completed en face 
through the corneal side. Tracer bead distribution in the TM of WT eyes was heterogeneous. A more homogeneous 
fluorescence pattern was observed in SPARC KO eyes, reflecting more uniform outflow. Gray portions of these 
images are from the projection of the brightfield lamp on the tissue and medium. Central portions of these images 
were removed due to iris autofluorescence. (C, D) Representative confocal microscopy of frontal sections of WT 
and KO high-tracer sections, respectively. Sclera, trabecular meshwork (TM), Schlemm’s canal (SC), ciliary body 
(CB), collector channel (CC), and episcleral vein (EV) are labeled. Tracer is strongly present throughout the TM. 
Tracer can also be noted within SC. (E) En face image of a high-tracer section demonstrating microbeads within the 












Figure 7. Percentage effective filtration length (PEFL) values in WT and KO eyes with SEM error bars. KO PEFL 
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(A)                    (B) 
Figure 8. (A) IOP-PEFL correlation (N=20, p<0.0001). The outlier (circle) and its matched point (arrow) are 
identified. (B) IOP-PEFL correlation with these points removed. R
2 increases significantly. 
 
 
Figure 9. Representative EM images of the four conditions with Schlemm’s canal (SC) labeled. (A) TM of a WT 
high-tracer region. Giant vacuole (*) labeled. (B) TM of a KO high-tracer region. Again, a vacuole can be seen. (C) 
TM of a WT low-tracer region, which appears quite compact. (D) TM of a KO low-tracer region, which is compact 
once again. 
 
*  * 
A" B"
C" D" 
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Figure 10. (A) Representative EM images of collagen fibrils in WT & KO high and low-tracer regions. Cross-
sections of the fibrils within the JCT can be observed. Schlemm’s Canal (SC) is labeled. (B) Comparison of average 
fibril diameter values between high & low-tracer regions of WT & KO tissue with SEM error bars. A total of 300 
fibrils per eye derived from 5 different sections of JCT were assessed. Both KO high and low-tracer values were 
significantly decreased compared to those of WT (N=3; p<0.0005).  
  65 
 
Figure 11. (A) Representative image of low-tracer region. No microbeads could be identified in the JCT region. 
Schlemm’s canal (SC) labeled. (B) Representative image of high-tracer region. Microbeads (*) are identified within 
the JCT. (C) High-tracer region near collector channel (CC) ostia. The JCT near the entrance to CC ostia (*) in high-
tracer regions appears less compact. The region encased in the black box is magnified in the next panel. (D) 
Collections of microbeads (*) were found in the open spaces of the JCT underneath a pore (arrow) amongst inner 
wall endothelial cells. Collector canal (CC) labeled.  
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Figure 12. IOP measurements under isoflurane. IOP is relatively stable after the fifth minute. The difference in IOP 
between WT (N=8 animals) and KO (N=8 animals) is statistically significant at all times. All IOPs in further 





Figure 13. Immunoblot analysis for TGFß2 and SPARC in anterior segment tissue. (A) Representative immunoblot 
bands demonstrating a significant increase in TGFß2 with Ad.TGFß2 infection in both WT and KO tissue. SPARC 
was also significantly increased by approximately 56% with Ad.TGFß2 infection. (B) Densitometric quantification 
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Figure 14. (A) Effects of Ad.TGFß2 injection on WT mice. IOPs of uninjected mice and mice injected with 
Ad.empty are also shown. The contralateral eye in the two treatment groups served as uninjected controls (“uninj.”). 
When compared to the IOPs of Ad.empty-injected WT mice, the IOP increase of Ad.TGFß2-injected WT mice is 
significant during days 4-11. (B) Effects of Ad.TGFß2 injection on KO mice. Compared to the IOPs of Ad.empty-
injected KO mice, the IOP increase of Ad.TGFß2-injected KO mice is not statistically significant at any time point. 





  68 
Table 1. P-values from two-way ANOVA with Bonferroni correction between the three treatment groups in WT and 
KO mice. 
Day  -1  4  6  8  11  13 
WT             
Ad.TGFß2 
vs. 
Ad.empty  >0.9999  0.0166  0.0230  <0.0001  0.0230  0.3522 
Ad.TGFß2 
vs. uninj.  >0.9999  0.0003  0.0004  <0.0001  0.0007  0.2800 
Ad.empty 
vs. uninj.  >0.9999   >0.9999  >0.9999  >0.9999  >0.9999  >0.9999 
KO             
Ad.TGFß2 
vs. 
Ad.empty  >0.9999  >0.9999  >0.9999  0.7518  0.7517  >0.9999 
Ad.TGFß2 
vs. uninj.  >0.9999  0.7150  0.1684  0.0385  0.1196  >0.9999 
Ad.empty 













Figure 15. Comparison of percentage increase in IOP of WT and KO mice injected with Ad.TGFß2 (N=8). The 
difference was statistically significant at Days 4, 6, and 8. Data is presented as mean ± SEM. *p<0.05.  
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Figure 16. Representative iridocorneal angle morphology of WT and KO mice 8 days after injection with either 





































Figure 17. Sagittal sections of representative WT and KO tissue stained for TGFß2. In both WT and KO mice, 
Ad.empty-injected eyes had a similar staining pattern to uninjected eyes. Ad.TGFß2-injected eyes demonstrated a 
marked increase in staining at Day 8 within the retina, vitreous humor, and trabecular meshwork. However, this 
effect was nullified at Day 13. Scale bar, 800 µm.  
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Figure 18. Changes in fluorescence intensity of select ECM proteins in (A) WT mice (B) KO mice 8 days after 
treatment with Ad.empty or Ad.TGFß2 (N=3). In WT tissue, the intensities of collagen IV, fibronectin, PAI-1, 
CTGF, and SPARC were significantly increased following TGFß2 stimulation (asterisks, p<0.05). In KO tissue, 
only PAI-1 and CTGF fluorescence increase were significant with TGFß2 stimulation (asterisks, p<0.05). Changes 





















Figure 19.  Representative immunolabeling of (A) collagen IV and (B) fibronectin in WT and KO mice 8 days after 
treatment with Ad.empty or Ad.TGFß2.  Both collagen IV and fibronectin were significantly increased in 
Ad.TGFß2-injected WT mice, but not in Ad.TGFß2-injected KO mice compared to respective Ad.empty groups. 
Mild fluorescence appeared in the TGFß2 panel of the Ad.empty-injected tissue, as the primary antibody was bound 
to endogenous mouse TGFß2. (C) Secondary antibody-only staining is shown as a negative control. Scale bar, 
10µm. 
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Figure 20.  Representative immunolabeling of (A) PAI-1, (B) CTGF, and (C) SPARC in WT and KO mice 8 days 
after treatment with Ad.empty or Ad.TGFß2.  PAI-1 and CTGF were significantly increased in both Ad.TGFß2-
injected WT mice and Ad.TGFß2-injected KO mice compared to respective Ad.empty groups. SPARC was 
upregulated in Ad.TGFß2-injected WT mice, and was absent in KO mice as expected. The fluorescent artifact in the 
SPARC panel of Ad.TGFß2 WT was not included in calculations, as it lies outside the TM. Mild fluorescence 
appeared in the TGFß2 panel of the Ad.empty-injected tissue, as the primary antibody was bound to endogenous 
mouse TGFß2. (D) Secondary antibody-only staining is shown as a negative control. Scale bar, 10µm. 
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Table 2. Fluorescence intensity measurements of ECM proteins and TGFß2 from immunostained images. P-values 


















ECM Protein  WT change (%)  KO change (%)  p-value 
Collagen I  32.07 ± 13.57  -11.12 ± 2.91  0.0965 
Collagen IV  55.13 ± 9.50  14.77 ± 12.17  0.0227 
Collagen VI  0.95 ± 1.34  13.23 ± 13.40  0.4605 
Laminin  26.38 ± 14.94  13.57 ± 15.92  0.4233 
Fibronectin  40.93 ± 6.54  -2.37 ± 9.31  0.0190 
PAI-1  64.64 ± 10.54  39.87 ± 6.42  0.2720 
CTGF  57.36 ± 14.41  64.75 ± 17.28  0.7040 
SPARC  48.64 ± 9.71  0  <0.001 
TGFß2  108.74 ± 12.16  78.38 ± 22.71  0.2582 